CG Oncology, Inc. Payments of Stock Issuance Costs
CG Oncology, Inc. (CGON) reported Payments of Stock Issuance Costs of $186.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-06
- CG Oncology, Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $139.00K, a 55.87% decline year-over-year.
- CG Oncology, Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $47.00K, a 79.74% decline year-over-year.
- CG Oncology, Inc. payments of stock issuance costs for the quarter ending 2025-06-30 was $315.00K.
- CG Oncology, Inc. payments of stock issuance costs for the quarter ending 2025-03-31 was $232.00K.
- CG Oncology, Inc. payments of stock issuance costs for fiscal 2025 was $316.00K, a 90.77% decline from fiscal 2024.
- CG Oncology, Inc. payments of stock issuance costs for fiscal 2024 was $3.42M, a 0.09% increase from fiscal 2023.
- CG Oncology, Inc. payments of stock issuance costs for fiscal 2023 was $3.42M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|
| 2026-06-30 | $139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $186.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $47.00K 10-Q · filed 2026-05-08 | ||
| 2025-12-31 | $316.00K 10-K · filed 2026-02-27 | ||
| 2025-06-30 | $315.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $547.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $232.00K 10-Q · filed 2026-05-08 | ||
| 2024-12-31 | $3.42M 10-K · filed 2026-02-27 | ||
| 2023-12-31 | $3.42M 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |